糖尿病肾病中SGLT2抑制剂与GLP-1受体激动剂的处方决策算法
本综述针对糖尿病肾病患者,提供决策工具以确定何时考虑使用SGLT2抑制剂和GLP-1受体激动剂进行心肾保护。文章首先讨论综合风险评估,比较两类药物在不同风险类别中的有效性,然后提出基于心血管和肾衰竭风险分层及证据强度的决策算法,并回顾不良反应及缓解策略。
要点
- SGLT2i和GLP-1 RA可预防心血管事件和肾衰竭,但临床采用缓慢。
- 决策算法基于心血管和肾衰竭风险分层及当前证据强度。
- 需评估不良反应并采取缓解策略。
核心结论
- 本综述提供了决策工具,帮助临床医生确定何时考虑使用SGLT2i和GLP-1 RA进行心肾保护。
研究设计与样本
- 综述文章,检索范围未明确报告。
主要发现
- SGLT2i和GLP-1 RA的临床试验改变了糖尿病治疗范式。
- 指南推荐超越血糖控制的整体方法,强调SGLT2i和GLP-1 RA的心肾保护。
- 针对糖尿病和高心血管及肾脏风险患者的SGLT2i和GLP-1 RA处方采用缓慢。
关键数值与推荐
- 使用心血管和肾衰竭风险分层及当前证据强度构建决策算法。
临床怎么用
- 临床医生可依据决策算法,结合心血管和肾衰竭风险分层及证据强度,决定是否处方SGLT2i和GLP-1 RA。
- 需评估不良反应并采取缓解策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diabetic kidney disease and its comorbid conditions, including atherosclerotic cardiovascular disease, heart failure, diabetes, and obesity, are interconnected conditions that compound the risk of kidney failure and cardiovascular mortality, and exponentiate health care costs. Sodium glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide 1 receptor agonist (GLP-1 RA) are novel diabetes medications that prevent cardiovascular events and kidney failure. Clinical trials exploring the cardiovascular and kidney outcomes of SGLT2i and GLP-1 RA have fundamentally shifted the treatment paradigm of diabetes. Clinical guidelines for diabetes management recommend a more holistic approach beyond glycemic control and emphasize heart and kidney protection of SGLT2i and GLP-1 RA. However, the adoption of prescribing SGLT2i and GLP-1 RA for patients with diabetes and high cardiovascular and kidney risk has been slow. In this review, we provide a decision-making tool to help clinicians determine when to consider SGLT2i and GLP-1 RA for heart and kidney protection. First, we discuss a comprehensive risk assessment for patients with diabetic kidney disease. We compare the effectiveness of SGLT2i and GLP-1 RA for different risk categories. Then, we present a decision algorithm using cardiovascular and kidney failure risk stratification and the strength of current evidence for the use of SGLT2i and GLP-1 RA. Lastly, we review the adverse effects of SGLT2i and GLP-1 RA and propose mitigation strategies.
引用
- Li J, Albajrami O, Zhuo M, et al. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2020. PMID: 32518100. doi:10.2215/CJN.02690320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。